Table 2.
Assessment of clinicopathological parameters predicting progression-free survival on univariate and multivariate analyses
| PFS univariate | PFS multivariate | |||||
|---|---|---|---|---|---|---|
| n | HR (95% CI) | p value | HR (95% CI) | p value | ||
| Age | 60</≤60 | 11/50 | 0.4890 (0.105–2.289) | 0.3632 | ||
| FIGO class | III, IV/I, II | 10/51 | 30.303 (7.353–125) | < 0.0001 | 19.608 (5.952–66.667) | < 0.0001 |
| Blood marker | Positive/negative | 48/13 | 0.806 (0.204–3.185) | 0.7583 | ||
| Histology | Clear cell/endometrioid | 41/20 | 2.212 (0.5778–8.475) | 0.2463 | ||
| Standard treatment | Incomplete/complete | 8/53 | 6.410 (1.488–27.778) | 0.0126 | 7.576 (1.828–31.25) | 0.0052 |
| SOD2 expression | High/low | 46/15 | 17.543 (1.825–166.667) | 0.0130 | 10 (1.271–76.923) | 0.0287 |
On univariate analysis, high expression of mitochondrial superoxide dismutase (SOD2), incompleteness of standard treatment, and high International Federation of Gynecology and Obstetrics (FIGO) stage were associated with poor prognosis. Multivariate Cox proportional hazards analysis also confirmed that high SOD2 expression, incompleteness of standard treatment, and high FIGO stage were significant prognostic factors for worse progression-free survival (PFS). CI confidence interval, HR hazards ratio